7PUS

ERK5 in complex with Pyrrole Carboxamide scaffold


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.59 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.219 

wwPDB Validation 

Currently 7PUS does not have a validation slider image.


This is version 1.0 of the entry. See complete history


Literature

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Miller, D.C.Reuillon, T.Molyneux, L.Blackburn, T.Cook, S.J.Edwards, N.Endicott, J.A.Golding, B.T.Griffin, R.J.Hardcastle, I.Harnor, S.J.Heptinstall, A.Lochhead, P.Martin, M.P.Martin, N.C.Myers, S.Newell, D.R.Noble, R.A.Phillips, N.Rigoreau, L.Thomas, H.Tucker, J.A.Wang, L.Z.Waring, M.J.Wong, A.C.Wedge, S.R.Noble, M.E.M.Cano, C.

(2022) J Med Chem 

  • DOI: 10.1021/acs.jmedchem.1c01756
  • Primary Citation of Related Structures:  
    7PUS

  • PubMed Abstract: 
  • The nonclassical extracellular signal-related kinase 5 (ERK5) mitogen-activated protein kinase pathway has been implicated in increased cellular proliferation, migration, survival, and angiogenesis; hence, ERK5 inhibition may be an attractive approach for cancer treatment ...

    The nonclassical extracellular signal-related kinase 5 (ERK5) mitogen-activated protein kinase pathway has been implicated in increased cellular proliferation, migration, survival, and angiogenesis; hence, ERK5 inhibition may be an attractive approach for cancer treatment. However, the development of selective ERK5 inhibitors has been challenging. Previously, we described the development of a pyrrole carboxamide high-throughput screening hit into a selective, submicromolar inhibitor of ERK5 kinase activity. Improvement in the ERK5 potency was necessary for the identification of a tool ERK5 inhibitor for target validation studies. Herein, we describe the optimization of this series to identify nanomolar pyrrole carboxamide inhibitors of ERK5 incorporating a basic center, which suffered from poor oral bioavailability. Parallel optimization of potency and in vitro pharmacokinetic parameters led to the identification of a nonbasic pyrazole analogue with an optimal balance of ERK5 inhibition and oral exposure.


    Organizational Affiliation

    Cancer Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 7A [auth AAA]358Homo sapiensMutation(s): 0 
Gene Names: MAPK7BMK1ERK5PRKM7
EC: 2.7.11.24
UniProt & NIH Common Fund Data Resources
Find proteins for Q13164 (Homo sapiens)
Explore Q13164 
Go to UniProtKB:  Q13164
PHAROS:  Q13164
GTEx:  ENSG00000166484 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ13164
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
86E (Subject of Investigation/LOI)
Query on 86E

Download Ideal Coordinates CCD File 
B [auth AAA]4-[3,6-bis(chloranyl)-2-fluoranyl-phenyl]carbonyl-~{N}-(1-methylpyrazol-4-yl)-1~{H}-pyrrole-2-carboxamide
C16 H11 Cl2 F N4 O2
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.59 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.219 
  • Space Group: P 41 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 91.671α = 90
b = 91.671β = 90
c = 113.81γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
REFMACrefinement
DIALSdata reduction
pointlessdata scaling
PHASERphasing

Structure Validation

Currently 7PUS does not have a validation slider image.




Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Medical Research Council (MRC, United Kingdom)United Kingdom--

Revision History  (Full details and data files)

  • Version 1.0: 2022-05-11
    Type: Initial release